Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Supplemental
Segments

Unit Economics
Common Size IS
Op Efficiency
Credit Analysis

LIGAND PHARMACEUTICALS INC (LGND)

Income Statement Business | Product

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Dec-31-22Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21
   10-Q10-Q8-K10-Q10-Q10-Q10-K10-Q
Total revenues   [+]186.8210.6203.1225.2224.0258.5277.1274.7
            Revenue growth  -16.6%-18.5%-26.7%-18.0%-11.0%24.0%48.7%91.5%
Cost of goods sold  68.268.368.340.740.744.047.247.5
Gross profit  118.6142.3134.8184.5183.2214.5230.0227.1
            Gross margin  63.5%67.6%66.4%81.9%81.8%83.0%83.0%82.7%
Selling, general and administrative   [+]70.771.572.659.254.557.157.870.1
Research and development  35.637.2 57.952.860.369.072.7
EBITDA   [+]25.239.6 77.792.0128.5130.0128.3
            EBITDA margin  13.5%18.8%15.6%34.5%41.1%49.7%46.9%46.7%
Depreciation and amortization  32.536.2 53.652.852.251.150.9
EBIT   [+]-7.23.4-8.724.239.276.378.977.4
            EBIT margin  -3.9%1.6%-4.3%10.7%17.5%29.5%28.5%28.2%
Interest expense, net   [+]-4.3-2.1-0.24.89.313.918.720.5
Other income (expense), net   [+]86.783.732.9-26.0-22.1-30.1-12.90.8
Pre-tax income  83.789.224.5-6.77.832.447.357.7
Income taxes  51.947.139.0-1.3-0.26.3-9.8-10.6
            Tax rate  62.0%52.8%159.0%19.7%  -20.8%-18.4%
Earnings from continuing ops  31.842.1-14.5-5.38.026.157.168.3
Earnings from discontinued ops    -3.0     
Net income  27.224.0-33.4-21.3-8.023.657.168.3
            Net margin  14.5%11.4%-16.4%-9.5%-3.6%9.1%20.6%24.9%
   
Basic EPS   [+]$1.87$2.49($0.86)($0.32)$0.48$1.56$3.44$4.14
Diluted EPS   [+]$1.82$2.44($0.85)($0.31)$0.47$1.53$3.32$4.03
   
Shares outstanding (basic)   [+]17.016.916.816.816.816.716.616.5
Shares outstanding (diluted)   [+]17.417.217.017.117.117.117.216.9
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy